Published in J Am Coll Cardiol on January 02, 2002
Stent fracture in revascularization for symptomatic ostial vertebral artery stenosis. Neuroradiology (2006) 1.49
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. J Geriatr Cardiol (2015) 1.10
Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart (2005) 0.98
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention. Heart Vessels (2012) 0.85
Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results. Eur Radiol (2003) 0.81
Risk:benefit assessment of old medicines. Br J Clin Pharmacol (2004) 0.77
Effect of atorvastatin and clopidogrel co-administration after coronary stenting in korean patients with stable angina. Korean Circ J (2011) 0.77
Controversies in the use & implementation of drug-eluting stent technology. Indian J Med Res (2012) 0.75
Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart (2005) 0.75
Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. J Atr Fibrillation (2015) 0.75
The P2Y(12) receptor as a target of antithrombotic drugs. Purinergic Signal (2011) 0.75
Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. Patient Relat Outcome Meas (2010) 0.75
Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol (2017) 0.75
Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). Int J Clin Exp Med (2015) 0.75
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vasc Health Risk Manag (2009) 0.75
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med (2010) 22.04
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol (2004) 5.67
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80
Can mobile health technologies transform health care? JAMA (2013) 4.75
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol (2004) 4.62
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med (2012) 4.47
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation (2004) 4.13
Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Drug-eluting coronary-artery stents. N Engl J Med (2013) 3.69
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol (2004) 3.67
Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol (2011) 3.66
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2007) 3.48
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Bare metal stent restenosis is not a benign clinical entity. Am Heart J (2006) 3.39
Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv (2011) 3.38
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv (2010) 3.24
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv (2005) 3.20
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol (2003) 3.13
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med (2004) 3.07
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01